FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W79859890> ?p ?o ?g. }

• W79859890 endingPage "315" @default.
• W79859890 startingPage "303" @default.
• W79859890 abstract "Objective In a randomized, double-blind, multicenter trial, ciprofloxacin/metronidazole was compared with imipenem/cilastatin for treatment of complicated intra-abdominal infections. A secondary objective was to demonstrate the ability to switch responding patients from intravenous (IV) to oral (PO) therapy. Summary Background Data Intra-abdominal infections result in substantial morbidity, mortality, and cost. Antimicrobial therapy often includes a 7-to 10-day intravenous course. The use of oral antimicrobials is a recent advance due to the availability of agents with good tissue pharmacokinetics and potent aerobic gram-negative activity. Methods Patients were randomized to either ciprofloxacin plus metronidazole intravenously (CIP/MTZ IV) or imipenem intravenously (IMI IV) throughout their treatment course, or ciprofloxacin plus metronidazole intravenously and treatment with oral ciprofloxacin plus metronidazole when oral feeding was resumed (CIP/MTZ IV/PO). Results Among 671 patients who constituted the intent-to-treat population, overall success rates were as follows: 82% for the group treated with CIP/MTZ IV; 84% for the CIP/MTZ IV/PO group; and 82% for the IMI IV group. For 330 valid patients, treatment success occurred in 84% of patients treated with CIP/MTZ IV, 86% of those treated with CIP/MTZ IV/PO, and 81% of the patients treated with IMI IV. Analysis of microbiology in the 30 patients undergoing intervention after treatment failure suggested that persistence of gram-negative organisms was more common in the IMI IV-treated patients who subsequently failed. Of 46 CIP/MTZ IV/PO patients (active oral arm), treatment success occurred in 96%, compared with 89% for those treated with CIP/MTZ IV and 89% for those receiving IMI IV. Patients who received intravenous/oral therapy were treated, overall, for an average of 8.6 ± 3.6 days, with an average of 4.0 ± 3.0 days of oral treatment. Conclusions These results demonstrate statistical equivalence between CIP/MTZ IV and IMI IV in both the intent-to-treat and valid populations. Conversion to oral therapy with CIP/MTZ appears as effective as continued intravenous therapy in patients able to tolerate oral feedings." @default.
• W79859890 created "2016-06-24" @default.
• W79859890 creator A5003906647 @default.
• W79859890 creator A5004819829 @default.
• W79859890 creator A5008843608 @default.
• W79859890 creator A5013136477 @default.
• W79859890 creator A5014353605 @default.
• W79859890 creator A5015636761 @default.
• W79859890 creator A5040506237 @default.
• W79859890 creator A5050331950 @default.
• W79859890 creator A5051689581 @default.
• W79859890 creator A5063938479 @default.
• W79859890 creator A5078514092 @default.
• W79859890 creator A5081360153 @default.
• W79859890 date "1996-03-01" @default.
• W79859890 modified "2023-09-25" @default.
• W79859890 title "Results of a Randomized Trial Comparing Sequential Intravenous/Oral Treatment with Ciprofloxacin Plus Metronidazole to Imipenem/Cilastatin for Intra-Abdominal Infections" @default.
• W79859890 cites W162125722 @default.
• W79859890 cites W1969494005 @default.
• W79859890 cites W1974843386 @default.
• W79859890 cites W1980813838 @default.
• W79859890 cites W1983466026 @default.
• W79859890 cites W1992058977 @default.
• W79859890 cites W1994111001 @default.
• W79859890 cites W1997423973 @default.
• W79859890 cites W1997960159 @default.
• W79859890 cites W2003417277 @default.
• W79859890 cites W2004449157 @default.
• W79859890 cites W2005488256 @default.
• W79859890 cites W2011422043 @default.
• W79859890 cites W2011483204 @default.
• W79859890 cites W2021526078 @default.
• W79859890 cites W2026219541 @default.
• W79859890 cites W2032388893 @default.
• W79859890 cites W2034137803 @default.
• W79859890 cites W2042674047 @default.
• W79859890 cites W2044432123 @default.
• W79859890 cites W2058008906 @default.
• W79859890 cites W2068379533 @default.
• W79859890 cites W2071219177 @default.
• W79859890 cites W2086773685 @default.
• W79859890 cites W2087973048 @default.
• W79859890 cites W2105874946 @default.
• W79859890 cites W2118523030 @default.
• W79859890 cites W2129403175 @default.
• W79859890 cites W2150478590 @default.
• W79859890 cites W2151770107 @default.
• W79859890 cites W2159325918 @default.
• W79859890 cites W2244655105 @default.
• W79859890 cites W2255152768 @default.
• W79859890 cites W2314688271 @default.
• W79859890 cites W2325297535 @default.
• W79859890 cites W2396236187 @default.
• W79859890 cites W2399936988 @default.
• W79859890 cites W2404194886 @default.
• W79859890 cites W2417980829 @default.
• W79859890 cites W2525777329 @default.
• W79859890 doi "https://doi.org/10.1097/00000658-199603000-00012" @default.
• W79859890 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1235120" @default.
• W79859890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8604912" @default.
• W79859890 hasPublicationYear "1996" @default.
• W79859890 type Work @default.
• W79859890 sameAs 79859890 @default.
• W79859890 citedByCount "183" @default.
• W79859890 countsByYear W798598902012 @default.
• W79859890 countsByYear W798598902013 @default.
• W79859890 countsByYear W798598902014 @default.
• W79859890 countsByYear W798598902015 @default.
• W79859890 countsByYear W798598902016 @default.
• W79859890 countsByYear W798598902017 @default.
• W79859890 countsByYear W798598902018 @default.
• W79859890 countsByYear W798598902019 @default.
• W79859890 countsByYear W798598902020 @default.
• W79859890 countsByYear W798598902021 @default.
• W79859890 countsByYear W798598902022 @default.
• W79859890 countsByYear W798598902023 @default.
• W79859890 crossrefType "journal-article" @default.
• W79859890 hasAuthorship W79859890A5003906647 @default.
• W79859890 hasAuthorship W79859890A5004819829 @default.
• W79859890 hasAuthorship W79859890A5008843608 @default.
• W79859890 hasAuthorship W79859890A5013136477 @default.
• W79859890 hasAuthorship W79859890A5014353605 @default.
• W79859890 hasAuthorship W79859890A5015636761 @default.
• W79859890 hasAuthorship W79859890A5040506237 @default.
• W79859890 hasAuthorship W79859890A5050331950 @default.
• W79859890 hasAuthorship W79859890A5051689581 @default.
• W79859890 hasAuthorship W79859890A5063938479 @default.
• W79859890 hasAuthorship W79859890A5078514092 @default.
• W79859890 hasAuthorship W79859890A5081360153 @default.
• W79859890 hasBestOaLocation W798598902 @default.
• W79859890 hasConcept C126322002 @default.
• W79859890 hasConcept C141071460 @default.
• W79859890 hasConcept C168563851 @default.
• W79859890 hasConcept C2777396551 @default.
• W79859890 hasConcept C2777437143 @default.
• W79859890 hasConcept C2778512257 @default.
• W79859890 hasConcept C2779499321 @default.
• W79859890 hasConcept C2779631663 @default.

• next